STEALTHYX THERAPEUTICS AND CANCER RESEARCH TECHNOLOGY ANNOUNCE CO-DEVELOPMENT PARTNERSHIP FOR TUMOUR-TARGETED THERAPY
Cancer Research Technology (CRT), the specialist oncology development and commercialisation
company, and Stealthyx Therapeutics, the disease targeting drug company spin out
of Queen Mary, University of London have entered into an agreement to co-develop
Stealthyx's proprietary drug delivery platform, Prothyx. The Prothyx platform
adds extra functionality to therapeutic molecules making them preferentially active
at sites of disease.